You are here

Hospital System Creates $10 EpiKit to Compete With EpiPen

Workaround offers blueprint for cost-conscious providers

Drugmaker Mylan has come under fire for hiking the price of its EpiPen, an epinephrine autoinjector for the treatment of life-threatening allergic reactions, by more than 450% since 2007. A pair of shots now costs around $600. But the University of Utah Health Care (UUHC) system, headquartered in Salt Lake City, has found a workaround that could provide a blueprint for other cost-conscious hospitals, according to an article posted on the Martketplace website.

For years, UUHC has stocked dozens of expensive EpiPens in many parts of its system, which includes four hospitals, a cancer institute, and 10 clinics. A $300 EpiPen was often close at hand. But now the EpiPen is giving way to EpiKits, which contain a vial of epinephrine, two needles, two syringes, alcohol wipes, and instructions. The kits cost around $10 each.

EpiPens feature an autoinjector system designed for consumers. EpiKits, on the other hand, are intended for medical staff who are used to handling syringes.

The EpiKits are expected to save UUHC approximately $35,000 a year––a drop in the bucket for the $3 billion health system.

Dr. Aaron Kesselheim of Brigham and Women’s Hospital in Boston told Marketplace that if the UUHC initiative is successful, he could see EpiKits catching on at hospitals across the country––and the modest economic impact could become a major one.

Mylan did not respond to a request for comments on the Marketplace article.

Source: Marketplace; November 2, 2016.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs